The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-01-10

AUTHORS

Josep Vidal, Samuel J. P. Malkin, Barnaby Hunt, Virginia Martín, Nino Hallén, Francisco Javier Ortega

ABSTRACT

IntroductionOnce-weekly semaglutide has been associated with greater reductions in glycated hemoglobin (HbA1c) and body weight than sitagliptin and dulaglutide in the SUSTAIN 2 and 7 clinical trials, respectively. These trials also assessed the proportions of patients achieving treatment targets capturing glycemic control and avoidance of hypoglycemia and weight gain. This study assessed the cost of bringing patients with type 2 diabetes to three clinically relevant endpoints with semaglutide versus sitagliptin and dulaglutide in Spain.MethodsThe proportions of patients achieving endpoints of HbA1c < 7.0%, HbA1c < 7.0% without hypoglycemia and without weight gain, and a ≥ 1.0% HbA1c reduction with ≥ 5.0% weight loss were taken from SUSTAIN 2 and 7. Cost of control was calculated as the annual per patient cost of each medication, expressed in 2019 euros (EUR), divided by the proportion of patients achieving each endpoint.ResultsBased on SUSTAIN 2, cost of control was lower for sitagliptin for the HbA1c < 7.0% endpoint, results were comparable for the HbA1c < 7.0% without hypoglycemia and without weight gain endpoint, and both doses of semaglutide were associated with lower costs of control for the ≥ 1.0% HbA1c reduction with ≥ 5.0% weight loss endpoint. Based on SUSTAIN 7, both doses of semaglutide were associated with lower costs of control for all three endpoints.ConclusionBoth doses of semaglutide were associated with comparable or lower costs of control versus sitagliptin when considering endpoints incorporating hypoglycemia and weight loss alongside glycemic control, and lower costs of control versus dulaglutide 1.5 mg for all endpoints in Spain.Plain Language SummaryPlain language summary available for this article. More... »

PAGES

509-521

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-019-00751-7

DOI

http://dx.doi.org/10.1007/s13300-019-00751-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1124008055

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31925724


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Diabetes y Enfermedades Metab\u00f3licas Asociadas (CIBERDEM), Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.430579.c", 
          "name": [
            "Endocrinology and Nutrition Department, Hospital Cl\u00ednic, Barcelona, Spain", 
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Diabetes y Enfermedades Metab\u00f3licas Asociadas (CIBERDEM), Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vidal", 
        "givenName": "Josep", 
        "id": "sg:person.01132216032.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132216032.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ossian Health Economics and Communications, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Ossian Health Economics and Communications, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Malkin", 
        "givenName": "Samuel J. P.", 
        "id": "sg:person.012067446720.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ossian Health Economics and Communications, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Ossian Health Economics and Communications, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hunt", 
        "givenName": "Barnaby", 
        "id": "sg:person.01346701147.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346701147.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk Pharma SA, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Novo Nordisk Pharma SA, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mart\u00edn", 
        "givenName": "Virginia", 
        "id": "sg:person.013364144073.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013364144073.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk A/S, S\u00f8borg, Denmark", 
          "id": "http://www.grid.ac/institutes/grid.425956.9", 
          "name": [
            "Novo Nordisk A/S, S\u00f8borg, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hall\u00e9n", 
        "givenName": "Nino", 
        "id": "sg:person.07745024772.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07745024772.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Campos-Lampreana Primary Healthcare Centre, Zamora, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Campos-Lampreana Primary Healthcare Centre, Zamora, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Javier Ortega", 
        "givenName": "Francisco", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1744-8603-9-17", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002296240", 
          "https://doi.org/10.1186/1744-8603-9-17"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-018-0402-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101625666", 
          "https://doi.org/10.1007/s13300-018-0402-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-018-0424-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103465312", 
          "https://doi.org/10.1007/s13300-018-0424-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-009-1472-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013300593", 
          "https://doi.org/10.1007/s00125-009-1472-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-01-10", 
    "datePublishedReg": "2020-01-10", 
    "description": "IntroductionOnce-weekly semaglutide has been associated with greater reductions in glycated hemoglobin (HbA1c) and body weight than sitagliptin and dulaglutide in the SUSTAIN\u00a02 and 7 clinical trials, respectively. These trials also assessed the proportions of patients achieving treatment targets capturing glycemic control and avoidance of hypoglycemia and weight gain. This study assessed the cost of bringing patients with type\u00a02 diabetes to three clinically relevant endpoints with semaglutide versus sitagliptin and dulaglutide in Spain.MethodsThe proportions of patients achieving endpoints of HbA1c\u2009<\u20097.0%, HbA1c\u2009<\u20097.0% without hypoglycemia and without weight gain, and a \u2265\u20091.0% HbA1c reduction with \u2265\u20095.0% weight loss were taken from SUSTAIN\u00a02 and 7. Cost of control was calculated as the annual per patient cost of each medication, expressed in 2019 euros (EUR), divided by the proportion of patients achieving each endpoint.ResultsBased on SUSTAIN\u00a02, cost of control was lower for sitagliptin for the HbA1c\u2009<\u20097.0% endpoint, results were comparable for the HbA1c\u2009<\u20097.0% without hypoglycemia and without weight gain endpoint, and both doses of semaglutide were associated with lower costs of control for the\u2009\u2265\u20091.0% HbA1c reduction with \u2265\u20095.0% weight loss endpoint. Based on SUSTAIN\u00a07, both doses of semaglutide were associated with lower costs of control for all three endpoints.ConclusionBoth doses of semaglutide were associated with comparable or lower costs of control versus sitagliptin when considering endpoints incorporating hypoglycemia and weight loss alongside glycemic control, and lower costs of control versus dulaglutide 1.5\u00a0mg for all endpoints in Spain.Plain Language SummaryPlain language summary available for this article.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-019-00751-7", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "keywords": [
      "proportion of patients", 
      "glycemic control", 
      "weight gain", 
      "weight loss", 
      "avoidance of hypoglycemia", 
      "treatment of patients", 
      "dulaglutide 1.5", 
      "daily sitagliptin", 
      "weekly dulaglutide", 
      "clinical trials", 
      "patient costs", 
      "semaglutide", 
      "body weight", 
      "patients", 
      "treatment targets", 
      "hypoglycemia", 
      "type 2", 
      "MethodsThe proportions", 
      "sitagliptin", 
      "HbA1c", 
      "relevant endpoints", 
      "endpoint", 
      "doses", 
      "greater reduction", 
      "trials", 
      "proportion", 
      "dulaglutide", 
      "medications", 
      "short term", 
      "control", 
      "hemoglobin", 
      "treatment", 
      "reduction", 
      "Versus", 
      "loss", 
      "target", 
      "weight", 
      "summary", 
      "study", 
      "control analysis", 
      "sustain", 
      "gain", 
      "avoidance", 
      "euro", 
      "Spain", 
      "types", 
      "analysis", 
      "cost", 
      "low cost", 
      "results", 
      "article", 
      "Language Summary", 
      "cost of control"
    ], 
    "name": "The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain", 
    "pagination": "509-521", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1124008055"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-019-00751-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31925724"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-019-00751-7", 
      "https://app.dimensions.ai/details/publication/pub.1124008055"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_840.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-019-00751-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-00751-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-00751-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-00751-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-00751-7'


 

This table displays all metadata directly associated to this object as RDF triples.

175 TRIPLES      21 PREDICATES      81 URIs      69 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-019-00751-7 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nf070af3d146041018f5eb463bc9adb5c
4 schema:citation sg:pub.10.1007/s00125-009-1472-y
5 sg:pub.10.1007/s13300-018-0402-8
6 sg:pub.10.1007/s13300-018-0424-2
7 sg:pub.10.1186/1744-8603-9-17
8 schema:datePublished 2020-01-10
9 schema:datePublishedReg 2020-01-10
10 schema:description IntroductionOnce-weekly semaglutide has been associated with greater reductions in glycated hemoglobin (HbA1c) and body weight than sitagliptin and dulaglutide in the SUSTAIN 2 and 7 clinical trials, respectively. These trials also assessed the proportions of patients achieving treatment targets capturing glycemic control and avoidance of hypoglycemia and weight gain. This study assessed the cost of bringing patients with type 2 diabetes to three clinically relevant endpoints with semaglutide versus sitagliptin and dulaglutide in Spain.MethodsThe proportions of patients achieving endpoints of HbA1c < 7.0%, HbA1c < 7.0% without hypoglycemia and without weight gain, and a ≥ 1.0% HbA1c reduction with ≥ 5.0% weight loss were taken from SUSTAIN 2 and 7. Cost of control was calculated as the annual per patient cost of each medication, expressed in 2019 euros (EUR), divided by the proportion of patients achieving each endpoint.ResultsBased on SUSTAIN 2, cost of control was lower for sitagliptin for the HbA1c < 7.0% endpoint, results were comparable for the HbA1c < 7.0% without hypoglycemia and without weight gain endpoint, and both doses of semaglutide were associated with lower costs of control for the ≥ 1.0% HbA1c reduction with ≥ 5.0% weight loss endpoint. Based on SUSTAIN 7, both doses of semaglutide were associated with lower costs of control for all three endpoints.ConclusionBoth doses of semaglutide were associated with comparable or lower costs of control versus sitagliptin when considering endpoints incorporating hypoglycemia and weight loss alongside glycemic control, and lower costs of control versus dulaglutide 1.5 mg for all endpoints in Spain.Plain Language SummaryPlain language summary available for this article.
11 schema:genre article
12 schema:isAccessibleForFree true
13 schema:isPartOf N8ed95a249eca4139b28648e866b98c73
14 Na4c067ca9b364c12a7de44a828f7a8d9
15 sg:journal.1044057
16 schema:keywords HbA1c
17 Language Summary
18 MethodsThe proportions
19 Spain
20 Versus
21 analysis
22 article
23 avoidance
24 avoidance of hypoglycemia
25 body weight
26 clinical trials
27 control
28 control analysis
29 cost
30 cost of control
31 daily sitagliptin
32 doses
33 dulaglutide
34 dulaglutide 1.5
35 endpoint
36 euro
37 gain
38 glycemic control
39 greater reduction
40 hemoglobin
41 hypoglycemia
42 loss
43 low cost
44 medications
45 patient costs
46 patients
47 proportion
48 proportion of patients
49 reduction
50 relevant endpoints
51 results
52 semaglutide
53 short term
54 sitagliptin
55 study
56 summary
57 sustain
58 target
59 treatment
60 treatment of patients
61 treatment targets
62 trials
63 type 2
64 types
65 weekly dulaglutide
66 weight
67 weight gain
68 weight loss
69 schema:name The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
70 schema:pagination 509-521
71 schema:productId N81abe164f3e14dd7b3e866898612ae94
72 Nbb384abdd17049fea244297735737c60
73 Nfbb839857d4e47b1b15a9064b79be605
74 schema:sameAs https://app.dimensions.ai/details/publication/pub.1124008055
75 https://doi.org/10.1007/s13300-019-00751-7
76 schema:sdDatePublished 2022-11-24T21:05
77 schema:sdLicense https://scigraph.springernature.com/explorer/license/
78 schema:sdPublisher N549d62f783084308985cea7325535073
79 schema:url https://doi.org/10.1007/s13300-019-00751-7
80 sgo:license sg:explorer/license/
81 sgo:sdDataset articles
82 rdf:type schema:ScholarlyArticle
83 N05305f227ff846539b1150b0dcd870cd schema:affiliation grid-institutes:None
84 schema:familyName Javier Ortega
85 schema:givenName Francisco
86 rdf:type schema:Person
87 N149533ff890f40f58055fc336d3ca688 rdf:first sg:person.012067446720.22
88 rdf:rest N349576a5bc9949a9b3eac0cd3cd0dfc5
89 N2519f3952eab445392f85c3cdac17e50 rdf:first sg:person.013364144073.37
90 rdf:rest Nd8777ceb3db349cfa04b80b1ae43830d
91 N349576a5bc9949a9b3eac0cd3cd0dfc5 rdf:first sg:person.01346701147.33
92 rdf:rest N2519f3952eab445392f85c3cdac17e50
93 N3a3e8cffaf504dc0be687918e42779c3 rdf:first N05305f227ff846539b1150b0dcd870cd
94 rdf:rest rdf:nil
95 N549d62f783084308985cea7325535073 schema:name Springer Nature - SN SciGraph project
96 rdf:type schema:Organization
97 N81abe164f3e14dd7b3e866898612ae94 schema:name dimensions_id
98 schema:value pub.1124008055
99 rdf:type schema:PropertyValue
100 N8ed95a249eca4139b28648e866b98c73 schema:volumeNumber 11
101 rdf:type schema:PublicationVolume
102 Na4c067ca9b364c12a7de44a828f7a8d9 schema:issueNumber 2
103 rdf:type schema:PublicationIssue
104 Nbb384abdd17049fea244297735737c60 schema:name doi
105 schema:value 10.1007/s13300-019-00751-7
106 rdf:type schema:PropertyValue
107 Nd8777ceb3db349cfa04b80b1ae43830d rdf:first sg:person.07745024772.02
108 rdf:rest N3a3e8cffaf504dc0be687918e42779c3
109 Nf070af3d146041018f5eb463bc9adb5c rdf:first sg:person.01132216032.56
110 rdf:rest N149533ff890f40f58055fc336d3ca688
111 Nfbb839857d4e47b1b15a9064b79be605 schema:name pubmed_id
112 schema:value 31925724
113 rdf:type schema:PropertyValue
114 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
115 schema:name Medical and Health Sciences
116 rdf:type schema:DefinedTerm
117 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
118 schema:name Clinical Sciences
119 rdf:type schema:DefinedTerm
120 sg:journal.1044057 schema:issn 1869-6953
121 1869-6961
122 schema:name Diabetes Therapy
123 schema:publisher Springer Nature
124 rdf:type schema:Periodical
125 sg:person.01132216032.56 schema:affiliation grid-institutes:grid.430579.c
126 schema:familyName Vidal
127 schema:givenName Josep
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132216032.56
129 rdf:type schema:Person
130 sg:person.012067446720.22 schema:affiliation grid-institutes:None
131 schema:familyName Malkin
132 schema:givenName Samuel J. P.
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22
134 rdf:type schema:Person
135 sg:person.013364144073.37 schema:affiliation grid-institutes:None
136 schema:familyName Martín
137 schema:givenName Virginia
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013364144073.37
139 rdf:type schema:Person
140 sg:person.01346701147.33 schema:affiliation grid-institutes:None
141 schema:familyName Hunt
142 schema:givenName Barnaby
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346701147.33
144 rdf:type schema:Person
145 sg:person.07745024772.02 schema:affiliation grid-institutes:grid.425956.9
146 schema:familyName Hallén
147 schema:givenName Nino
148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07745024772.02
149 rdf:type schema:Person
150 sg:pub.10.1007/s00125-009-1472-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1013300593
151 https://doi.org/10.1007/s00125-009-1472-y
152 rdf:type schema:CreativeWork
153 sg:pub.10.1007/s13300-018-0402-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101625666
154 https://doi.org/10.1007/s13300-018-0402-8
155 rdf:type schema:CreativeWork
156 sg:pub.10.1007/s13300-018-0424-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103465312
157 https://doi.org/10.1007/s13300-018-0424-2
158 rdf:type schema:CreativeWork
159 sg:pub.10.1186/1744-8603-9-17 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002296240
160 https://doi.org/10.1186/1744-8603-9-17
161 rdf:type schema:CreativeWork
162 grid-institutes:None schema:alternateName Campos-Lampreana Primary Healthcare Centre, Zamora, Spain
163 Novo Nordisk Pharma SA, Madrid, Spain
164 Ossian Health Economics and Communications, Basel, Switzerland
165 schema:name Campos-Lampreana Primary Healthcare Centre, Zamora, Spain
166 Novo Nordisk Pharma SA, Madrid, Spain
167 Ossian Health Economics and Communications, Basel, Switzerland
168 rdf:type schema:Organization
169 grid-institutes:grid.425956.9 schema:alternateName Novo Nordisk A/S, Søborg, Denmark
170 schema:name Novo Nordisk A/S, Søborg, Denmark
171 rdf:type schema:Organization
172 grid-institutes:grid.430579.c schema:alternateName Centro de Investigación Biomédica en Red en Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain
173 schema:name Centro de Investigación Biomédica en Red en Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain
174 Endocrinology and Nutrition Department, Hospital Clínic, Barcelona, Spain
175 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...